National Coverage Analysis (NCA) View Public Comments

Positron Emission Tomography

Public Comments

Commenter Comment Information
Abraham, Brian Title: Sr Policy Director
Organization: MITA
Date: 01/11/2013
Comment:

January 11, 2013

Louis Jacques, MD
Director, Coverage and Analysis Group
Centers for Medicare and Medicaid Services
7500 Security Boulevard
Baltimore, Maryland 21244

RE: Comment on National Coverage Determination Decision Memorandum for Positron Emission Tomography (CAG-00065R)

Dear Dr. Jacques:

The Medical Imaging & Technology Alliance (MITA) thanks the Centers for Medicare and Medicaid Services (CMS) for posting its

More

Pitts, Aaron Title: Sr Vice President, Sales & Marketing
Organization: Cardinal Health Nuclear Pharmacy Services
Date: 01/11/2013
Comment:

Dear Dr. Jacques-

Cardinal Health is pleased to respond to the Centers for Medicaid and Medicare Services (CMS) request for comments on the reconsideration request of Section 220.6 of the National Coverage Determinations (NCD) Manual, dealing with Positron Emission Tomography or PET imaging. Cardinal Health’s Nuclear Pharmacy Services dispenses over 12 million nuclear medicine and PET radiopharmaceutical doses annually in the United States. We also provide support for more than

More

Bunning, Sue Title: Director, Health Policy & Regulatory Affairs
Organization: SNMMI, ACR, ACC, ASNC
Date: 01/11/2013
Comment:

January 11, 2013

Louis Jacques, M.D.
Director, Coverage and Analysis Group
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244

RE: Proposed Decision Memo for Positron Emission Tomography (CAG-00065R2)

Dear Dr. Jacques:

The Society of Nuclear Medicine and Molecular Imaging (SNMMI), the American College of Radiology (ACR), the American College of Cardiology (ACC) and the American Society of Nuclear

More

Bhujwalla, Zaver Title: President
Organization: World Molecular Imaging Society
Date: 01/11/2013
Comment:

The World Molecular Imaging Society (WMIS) appreciates the effort by the Centers for Medicare & Medicaid Services (CMS) over the past year to revise the national coverage policy for Positron Emission Tomography (PET) imaging. WMIS strongly supports the Proposed Decision Memorandum proposal to permit local contractors to determine coverage for new oncologic PET radiopharmaceuticals approved by the U.S. Food and Drug Administration (FDA).

However, WMIS remains concerned that the

More

Kiepert, Jr., Donald R. Date: 01/10/2013
Comment:

Dear Dr. Jacques:

Lantheus Medical Imaging, Inc. (Lantheus) appreciates the opportunity to submit comments to the Centers for Medicare and Medicaid Services (CMS) regarding the above-referenced Proposed Decision Memo for Positron Emission Tomography (PET).

Lantheus is the developer and manufacturer of a number of radiopharmaceuticals used for nuclear cardiology and nuclear medicine procedures, including Cardiolite® (Kit for the Preparation of Technetium Tc99m

More

Arrighi, MD, James Title: President
Organization: American Society of Nuclear Cardiology
Date: 01/07/2013
Comment:

Louis Jacques, MD
Director, Coverage and Analysis Group
Centers for Medicare and Medicaid Services
7500 Security Boulevard
Baltimore, Maryland  21244

RE:     Proposed Decision Memo for Positron Emission Tomography (CAG-00065R2)

Dear Dr. Jacques:

The American Society of Nuclear Cardiology (ASNC) and American College of Cardiology (ACC) appreciate the opportunity to submit comments to the Centers for Medicare and Medicaid

More

Webner, Peter Date: 12/17/2012
Comment:

Allowing MAC discretion for coverage of oncologic applications for PET drugs is a very positive move forward. Any drug being put through the current FDA approval process whether generic or a new molecular entity must show safety and efficacy for a relatively narrow range of applications.
These actions help streamline the process for coverage post approval and will streamline access to these powerful diagnostic compounds for clinicians and patients.

I am hoping that CMS will

More